A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy
NCT00036621
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
INDUSTRY
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
BMS-275291
Sponsor
Bristol-Myers Squibb